ESOMO 35: Chemotherapeutical Phase III Trial Shows Positive Response to Treat Multiple Myeloma

Recommend to others!
According to the study done by the 35th Congress of the European Society for Medical Oncology (ESMO), the phase III trial conducted over 402 patients has showed positive response for the treatment of multiple myeloma.
To begin with, all the patients were administered an introductory treatment of the new drug called lenalidomide along with dexamethasone in little quantity. The following day, all of them arbitrarily assigned to one of two consolidation treatments.
The first group comprising 202 patients got traditional treatment with an integration of melphalan and prednisone including lenalidomide. The second group comprising 200 patients was administered high-dose melphalan with additional autologous transplants of their own stem cells.
When the introductory treatment was done, the research found that 83% of patients gave a nominal response. So to say, the level of paraprotein in their blood had decreased by half. On the other hand, 34% of patients showed a good partial response say, 90% abatement in paraprotein was detected.  6% of the remaining patient’s group gave a complete response. So to say, the paraprotein level in their blood was not traced.
Dr Palumbo is quite pleased with the response seen in the patents. “We are pleased with the results because both treatments showed good qualitative response achieved with the induction regimen of lenalidomide and dexamethasone.”
Adding further he said that this is the first study which relatively has shown much improvement than the conventional dose chemotherapy plus new drugs.

According to the study done by the 35th Congress of the European Society for Medical Oncology (ESMO), the phase III trial conducted over 402 patients has showed positive response for the treatment of multiple myeloma. To begin with, all the patients were administered an introductory treatment of the new drug called lenalidomide along with dexamethasone in little quantity. The following day, all of them arbitrarily assigned to one of two consolidation treatments. The first group comprising 202 patients got traditional treatment with an integration of melphalan and prednisone including lenalidomide. The second group comprising 200 patients was administered high-dose melphalan with additional autologous transplants of their own stem cells. When the introductory treatment was done, the research found that 83% of patients gave a nominal response. So to say, the level of paraprotein in their blood had decreased by half. On the other hand, 34% of patients showed a good partial response say, 90% abatement in paraprotein was detected.  6% of the remaining patient’s group gave a complete response. So to say, the paraprotein level in their blood was not traced. Dr Palumbo is quite pleased with the response seen in the patents. “We are pleased with the results because both treatments showed good qualitative response achieved with the induction regimen of lenalidomide and dexamethasone.”Adding further he said that this is the first study which relatively has shown much improvement than the conventional dose chemotherapy plus new drugs.

Comments

comments

Speak Your Mind

*

Current day month ye@r *